compound introduction
Information GSK'963 GSK'963 is a chiral small-molecule inhibitor of RIP1 kinase (RIPK1) with an IC50 of 29 nM in FP binding assays. It is >10 000-fold selective for RIP1 over 339 other kinases. Targets RIP1 kinase (Cell-free assay) 29 nM In vitro GSK\'963 inhibits RIP1-dependent cell death with an IC50 of between 1 and 4\u2009nM in human and murine cells. In vivo GSK\'963 is a potent inhibitor of a TNF+zVAD-mediated lethal shock. At 2\u2009mg/kg, GSK\'963 would maintain blood concentrations above the concentration required for 90% inhibition of RIP1 activity for an extended period of time compared with Nec-1. Cell Research(from reference) Cell lines：BMDM Concentrations：100\u2009nM Incubation Time：30 min
